Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Politico's article about Novavax's inability to manufacture its Covid-19 vaccine wasn't good for NVAX stock. Down 16% since, should you buy?

Novavax Just Caught a Big Break

American Well Corporation

Novocure

You might want to avoid stuffing your portfolio with them.

3 Healthcare Stocks That Could Be Turkeys in November

Novavax Inc. NVAX, +6.41% said Friday it has filed for provisional approval of its COVID-19 vaccine in Australia. "The company's application to the TGA marks the first complete application for provisional approval of a protein-based COVID-19 vaccine in Australia," the company said in a statement.

Novavax files for provisional approval of COVID-19 vaccine in Australia

GAITHERSBURG, Md., Oct. 29, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the completion of its rolling submission to the Therapeutic Goods Administration (TGA) for provisional approval of its COVID-19 vaccine candidate.

Novavax Files for Provisional Approval of its COVID-19 Vaccine in Australia

Can Novavax Make a Comeback?

BioNTech SE

Comirnaty, the COVID-19 vaccine produced by Pfizer-BioNTech, has been recommended for children between 5 and 11 years old. The White House has acquired sufficient vaccines from Pfizer-BioNTech. It is targeted for distribution to more than 25,000 pediatricians' offices, hospitals, and pharmacies.

Novavax Is Finally Coming For BioNTech's Dominance

Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Novavax (NVAX) Q3 Earnings Expected to Decline

NVAX stock has suffered some setbacks, but with only half the world population vaccinated, patient investors are likely to be rewarded. The post Don't Count Novavax Out; The World Still Needs Vaccines appeared first on InvestorPlace.

Don't Count Novavax Out; The World Still Needs Vaccines

The company's shares sunk on news of production-related issues last week.

Worried About Novavax? Here's What You Can Do to Minimize Your Risk

Novavax may be on the verge of good news from U.K. regulators. NVAX stock is reacting well to the impending news.

NVAX Stock Soars 6% as Novavax Reaches Key Vaccine Milestone

After a protracted delay, Novavax, Inc. (NASDAQ: NVAX) is finally making some headway with its COVID-19 vaccine candidate – NVXCoV2373. What Happened: Maryland-based Novavax said it has completed its rolling regulatory submission to the U.K. Medicines and Healthcare products Regulatory Agency for authorization of NVXCoV2373.

Novavax Rips Higher After Completing Regulatory Filing For Authorization Of COVID-19 Vaccine In UK

While it has been nearly a year since Pfizer and Moderna's Covid-19 vaccines hit the market, Novavax has yet to commercially deploy its shot, amid persistent production and quality issues.

What's Next For Novavax Stock After A Large 46% Fall In A Month?

Shares of Novavax Inc. NVAX, -0.27% jumped 8.0% in premarket trading on Wednesday after the company said it began submitting its experimental COVID-19 vaccine for authorization in the U.K. Novavax's vaccine candidate is protein-based, meaning it's a different type of vaccine than the mRNA shots developed by BioNTech SE BNTX, -0.86% /Pfizer Inc. PFE, +0.95% and Moderna Inc. MRNA, -1.09% or the ChAdOx1 technology used in the AstraZeneca AZN, +0.79% shots. Novavax's vaccine came out of clinical trials in the U.K. with an overall efficacy rate of 89.7%.

Novavax is seeking authorization in the U.K. for its COVID-19 vaccine

Filing marks first protein-based COVID-19 vaccine submitted to MHRA for authorization All modules required for regulatory review, including CMC data, are now complete Submission based on Phase 3 data from ~45K patients demonstrating high efficacy and well-tolerated safety, including against variants Submissions to additional global regulatory authorities including EU, Canada and Australia expected soon GAITHERSBURG, Md., Oct. 27, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the completion of its rolling regulatory submission to the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for authorization of its COVID-19 vaccine candidate.

Novavax Files for Authorization of its COVID-19 Vaccine in the United Kingdom

After a stellar 2020 run, the stock is 60% off its highs.

What's Going On With Novavax Stock?

San Francisco, California--(Newsfile Corp. - October 26, 2021) -  Hagens Berman urges Novavax, Inc. (NASDAQ: NVAX) investors with significant losses to submit your losses now.Visit: www.hbsslaw.com/investor-fraud/NVAX Contact An Attorney Now: NVAX@hbsslaw.com 844-916-0895Novavax, Inc. (NVAX) Investigation: The U.S. government invested approximately $1.6 billion in Novavax in 2020 in the hopes it would offer a safe and effective vaccine to help protect against COVID-19. The investigation focuses on...

NVAX INVESTIGATION: Hagens Berman, National Trial Attorneys, Encourages Novavax (NVAX) Investors with Significant Losses to Contact Firm's Attorneys Now, Firm Investigating Possible Securities Law Violations

Los Angeles, California--(Newsfile Corp. - October 26, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or "the Company") (NASDAQ: NVAX) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Novavax is the subject of an article published by Politico on October...

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Novavax, Inc. and Encourages Investors with Losses of $500,000 to Contact the Firm

Boston, Massachusetts--(Newsfile Corp. - October 26, 2021) - Block & Leviton is investigating Novavax Inc. (NASDAQ: NVAX) for potential securities law violations. Investors who have lost money in their Novavax Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/nvax.What is this all about?On October 19, 2021, after the market closed, Politico published an article, titled "'They Rushed the Process': Vaccine Maker's woes hamper...

NOVAVAX INVESTIGATION: Block & Leviton Is Investigating Novavax Inc. For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

When the race to develop a Covid-19 vaccine began in early 2020, Novavax stock (NASDAQ: NVAX) was viewed as one of the front runners, with the company securing the largest funding from the U.S. government (about $1.6 billion). However, over a year and a half later, Novavax has yet to commercially.

Novavax Hasn't Delivered A Vaccine Yet, But The Stock May Be Worth A Look

After recent events, this biotech may be trading at a bargain.

This Popular Stock Has a 93% Upside, According to Wall Street

Atea Pharmaceuticals

Johnson & Johnson

Ghosts, goblins, ghouls? No, it's three vaccine stocks.

3 Top COVID Stocks -- Are They Tricks or Treats?

NVAX stock is even more of a gamble thanks to manufacturing issues, but the next move for the beaten-down shares could still be up. The post Novavax is Now a Riskier Play, but Still One to Keep Your Eye On appeared first on InvestorPlace.

Novavax is Now a Riskier Play, but Still One to Keep Your Eye On

LOS ANGELES--(BUSINESS WIRE)---- $NVAX #investors--The Law Offices of Frank R. Cruz Announces Investigation of Novavax, Inc. (NVAX) on Behalf of Investors

The Law Offices of Frank R. Cruz Announces Investigation of Novavax, Inc. (NVAX) on Behalf of Investors

LOS ANGELES, Oct. 25, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or "the Company") (NASDAQ: NVAX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Novavax, Inc. and Encourages Investors with Losses of $500,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)-- #Novavax--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Novavax, Inc. (“Novavax” or the “Company”) (NASDAQ: NVAX) on behalf of Novavax stockholders. Our investigation concerns whether Novavax has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On October 19, 2021, after the market closed, Politico published an artic

NOVAVAX ALERT: Bragar Eagel & Squire, P.C. Is Investigating Novavax, Inc. on Behalf of Novavax Stockholders and Encourages Investors to Contact the Firm

News for Novavax Stock (NVAX)